Skip to main content
. 2010 Dec 29;117(13):3505–3513. doi: 10.1182/blood-2010-08-301929

Figure 2.

Figure 2

Unadjusted overall survival in patients taking rituximab plus chemotherapy, chemotherapy alone, and rituximab monotherapy. (A) chemotherapy alone (CT alone) has the solid line (lower curve), and rituximab plus chemotherapy (R + CT) has the dashed line. (B) Rituximab monotherapy. Curves represent the survival estimate and the 95% confidence interval. Numbers at the bottom of the figures indicate the number of patients under observation at each time point.